A randomised, open label, controlled trial on the effect of interferon plus amantadine compared with interferon alone for treatment of chronic hepatitis C

Baisini, Ornella; Pigozzi, M.G.; Benini, Federica; Stellini, Roberto; Alessandro, Riccardo; Daniela, Quattrocchi; Salmi, Andrea; Andri, G; Anna, Cominotti; Favret, M; Gargiulo, Franco; Lanzini, Alberto

doi:10.1016/s1386-6346(03)00111-6

Cited by 9 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased pretreatment serum γGT levels with normal ALP is frequently observed in patients with chronic hepatitis C, and more often than in other forms of viral hepatitis 8,9 . In our own experience 54% and 46%, respectively, of 199 total patients with chronic hepatitis C entering two prospective treatment trials 10,11 had increased pretreatment serum γGT levels. These proportions are far higher than the 22% for men and 16% for women recently reported by Ruttmann et al 12 .…”

Section: Introductionmentioning

confidence: 75%

Increased serum gamma‐glutamyl‐transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C

Benini¹,

Pigozzi²,

Ornella³

et al. 2006

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 75%

Increased serum gamma‐glutamyl‐transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C

Benini¹,

Pigozzi²,

Ornella³

et al. 2006

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…AMD had been reported to be effective in treating patients with hepatitis C (23, 24) but confirmation of its effectiveness as monotherapy has proved elusive (25) and a plausible mechanism of action (26) remains to be established. The combination of interferon plus AMD was effective in one trial of 200 patients (14) and in a trial of elderly patients (27), but it was generally ineffective in most clinical trials (15)(16)(17)(18)(19)(20). The combination of interferon plus AMD was also generally ineffective in patients nonresponsive to interferon alone (28)(29)(30)(31) or interferon plus RBV (30).…”

Section: Discussionmentioning

confidence: 99%

“…AMD, which has been used primarily for the prophylaxis and treatment of respiratory tract infections caused by influenza A virus, is believed to prevent the entry of viruses into host cells (12). In patients with chronic HCV infection, the addition of AMD to interferon or interferon plus RBV treatment regimens has shown conflicting results (13)(14)(15)(16)(17)(18)(19)(20).…”

mentioning

confidence: 99%

Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

et al. 2005

View full text Add to dashboard Cite

There are no established therapeutic regimens for hepatitis C virus (HCV) patients who relapse following treatment with interferon α-2b and ribavirin or those who break through while on interferon α-2b and ribavirin. We therefore evaluated various combination therapies in HCV patients who relapsed or experienced a viral breakthrough. Patients (n = 124) were randomized to 48 weeks of treatment with once-weekly subcutaneous injections of 180 µg pegylated (peg-) interferon α-2a plus oral ribavirin (800-1000 mg/day), mycophenolate mofetil (2 g/day), amantadine (200 mg/day), or ribavirin and amantadine and followed for an additional 24 weeks. The sustained virologic response was higher in patients administered peginterferon α-2a plus ribavirin (38%) or ribavirin and amantadine (45%) than in those administered peginterferon α-2a plus mycophenolate mofetil (17%) or amantadine (10%). As in previous studies, patients with genotype non-1 and those with lower viral loads had better responses than those with genotype 1 and high viral loads, though the differences did not reach significance. The four treatment regimens had similar safety profiles, except that patients receiving ribavirin had greater maximal hemoglobin decreases. These findings suggest that the combination of peginterferon α-2a plus ribavirin or with ribavirin and amantadine is effective in some HCV patients who relapse after treatment with interferon α-2b plus ribavirin.

show abstract

“…Although amantadine appeared to provide benefit in a few trials in naive 353 and nonresponder 354 patient cohorts, most RCTs showed no benefit associated with amantadine therapy. [355][356][357][358][359] Therefore, amantadine cannot be recommended as a component of antiviral therapy for chronic hepatitis C.…”

Section: Other Medical Therapiesmentioning

confidence: 99%

American Gastroenterological Association Technical Review on the Management of Hepatitis C

2006

View full text Add to dashboard Cite

A randomised, open label, controlled trial on the effect of interferon plus amantadine compared with interferon alone for treatment of chronic hepatitis C

Cited by 9 publications

References 28 publications

Increased serum gamma‐glutamyl‐transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C

Increased serum gamma‐glutamyl‐transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C

Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

American Gastroenterological Association Technical Review on the Management of Hepatitis C

Contact Info

Product

Resources

About